Leo International Group Embarks on a Century-Old Journey with Altruism at Its Core, Set for NASDAQ Listing SeaPRwire

Leo International Group Embarks on a Century-Old Journey with Altruism at Its Core, Set for NASDAQ Listing

Singapore, 2024 - November 01, 2024 - (SeaPRwire) - Leo International Group, a family business founded in 1938, has grown to become Asia's largest top-tier brand agency distribution group, operating across a diverse range of industries, including private butler services, charity, religion, trade, warehousing, logistics, catering, and education. According to a report currently published by "The Icons" , Leo Wang, Chairman and Founder of Leo International Group, has built the company with a strong commitment to "altruism" and century-old heritage at its foundation. As the eldest son of the fourth generation, Leo Wang has been inspired by the concept of " century-old inheritance" from a young age. His deep passion for history has driven him to study century-old brands from China and abroad. Through his exploration, Wang discovered that while innovation is essential for businesses to adapt to different eras, the true key to success lies in the leadership's mission and vision. For Wang, maintaining a focus on contributing to the greater good and creating virtuous cycles for both society and the company is crucial for a long-lasting enterprise. "Our family legacy has always been about contributing to the world," Wang shared. "Whether through social charity or my roles as a general manager in century-old foreign companies, the focus has always been on how we can create value not just for individuals but for the world at large." Since its founding in 2016, Leo International Group has rapidly expanded to become Asia's leading top-tier brand agency distribution group. Over the past five years, the company has formed partnerships with more than 170 international luxury brands and manages 4,600 private jets across 300 cities globally. In addition to these achievements, Leo International Group offers membership privileges at over 5,000 luxury hotels worldwide and is highly regarded as Asia's "leading guide to top-tier lifestyle." Wang attributes the group's impressive global development to embedding the spirit of "altruism" into the very DNA of the company. The group's "win-win" collaborations with its hundreds of partner brands have fostered long-lasting relationships and created mutually beneficial outcomes. "The founders of century-old brands have a dual focus," Wang explained. "One is the continuous pursuit of business success, and the other is their dedication to the world. The core soul of a century-old inheritance must be empathy with the world." This altruistic philosophy has not only propelled Leo International Group's success but has also influenced its partners. The company integrates businesses from across different industries, including health seminars, asset trend seminars, art, technology, equestrianism, yachting, supercars, luxury goods, and more. These offerings provide a comprehensive lifestyle service to their elite clients, ensuring that their needs are met through seamless and personalized experiences. In addition to its business success, Leo International Group places a strong emphasis on corporate social responsibility. Under Wang's leadership, the company has been a long-time supporter of the Chinese Childrenhome & Shelter Association (CCSA), focusing on child welfare and education. Wang believes that education is the foundation of societal progress and that supporting the next generation is critical for the future. "Orphanages typically care for children until they turn 15, but I believe the decade after they leave is equally important in shaping their lives," Wang explained. "During those critical ten years, the people they meet and the experiences they have will influence them for the rest of their lives." CCSA provides not only care and financial support for living and education but also mentorship programs. Successful young individuals, who were once supported by the association, return to share their stories and mentor the younger generation. These mentors now hold positions at top companies like TSMC and Microsoft, using their experiences to inspire and guide children who face similar challenges. Wang's dedication to education stems from his own upbringing. His mother, a nun involved in social welfare, instilled in him the importance of giving back to society. "From a young age, I saw people coming to my mother for help, and she always believed in taking from society and giving back," Wang shared. As Leo International Group continues to expand, its leadership remains committed to Wang's vision of altruism and societal contribution. The company is currently preparing for a listing on the US NASDAQ, expected within the next 18 to 36 months. This milestone is part of the group's broader plan for global expansion. Already a leader in Asia, the group operates across key cities including Taiwan, Hong Kong, Singapore, and Kuala Lumpur, and is now setting its sights on Europe and the Americas. "Heading towards a NASDAQ listing is not just about business growth; it's about amplifying our impact on the world," Wang explained. "Our mission has always been about integrating resources to make the world a better place." The company's future plans include further expansion into cities like Sanya, Ho Chi Minh City, Hanoi, Jakarta, Tokyo, and Dubai. Early 2024 will see a series of VIP events in collaboration with private banks, investment banks, and yacht clubs, offering luxury seminars on health, asset trends, and more. These events will be held in major Asian cities such as Hong Kong, Shanghai, Singapore, and Taipei, with additional expansions planned for Europe and North America post-IPO. Leo International Group's business scope spans across industries and sectors, with plans to further integrate over 33 cross-industry brand partners. Wang likens his business model to a "top-tier lifestyle version of Berkshire Hathaway," rapidly acquiring businesses and investing in companies with strong growth potential. "As our business grows, so does our responsibility," Wang said. "We will continue to invite outstanding leaders from all walks of life to join us in making the world a better place."
More

新鸿基公司投资于ActusRayPartners新推出的日本阿尔法基金 – ActusRayPartners Japan Alpha Fund

EQS 新闻 via SEAPRWire.com / 2024-11-01 / 13:06 UTC+8 新鸿基有限公司 (香港股份代号:86) (「新鸿基公司」)及旗下持牌基金管理平台Sun Hung Kai Capital Partners Limited欣然宣布,投资于2024年9月26日启动的ActusRayPartners日本阿尔法基金(ActusRayPartners Japan Alpha Fund)(「该基金」)。这是新鸿基公司继对ActusRayPartners亚洲及欧洲策略持续投资后的新增投资。其他ActusRayPartners现有客户也对此日本策略表达了初步的兴趣。该基金采用股票长短仓和接近市场中性策略,旨在透过识别及捕捉日本股票市场的低效性来产生阿尔法收益。ActusRayPartners采用其「自主概率投资」(Discretionary Probabilistic Investing)方式,通过结合量化基础与自主调整,以应对纯粹量化交易的盲点。 这是ActusRayPartners继 2020 年和 2022 年分别成功推出欧洲策略及亚洲策略基金后,再推出的第三只阿尔法策略基金。欧洲策略基金于2023及2024年荣获「HFM 欧洲对冲基金表现大奖」,而亚洲策略基金则于2024年荣获「HFM 亚太区对冲基金表现大奖」。ActusRayPartners是一家总部位于香港的资产管理公司,由安力德 (Andrew Alexander)、陈兆伟(Raymond Chan)和张泓(Patrick Cheung) 于2019年共同平等创立。多位团队成员曾于麦格理量化对冲基金部门工作。目前, ActusRayPartners在香港及悉尼共拥有27名成员,负责管理亚洲、欧洲及日本逾7亿美元的资金。新鸿基公司副行政总裁 Tony Edwards 表示:「恭喜 ActusRayPartners再次推出新基金。自 2020 年以来,新鸿基公司很荣幸能够提供种子投资以及支持 ActusRayPartners的发展,而这项进一步的承诺强调了我们对其能力的信心,并反映我们之间的投资目标完美契合。」ActusRayPartners的三位共同创始人表示:「日本阿尔法策略的推出对我们而言是一个令人振奋的里程碑。我们衷心感谢新鸿基公司多年来的支持。我们期待运用我们的『自主概率投资』方式,为投资者捕捉日本股票市场的阿尔法收益。」高盛和摩根士丹利是 ActusRayPartners日本阿尔法基金的主要经纪商。Morgan Stanley Fund Services和开曼群岛罗兵咸永道会计师事务所分别是该基金的管理人和核数师。高伟绅律师事务所和汇嘉律师事务所分别是其国际法律顾问和开曼群岛法律顾问。 – 完 – 关于ActusRayPartnersActusRayPartners是一家总部位于香港的资产管理公司,由安力德 (Andrew Alexander)、陈兆伟(Raymond Chan)和张泓(Patrick Cheung) 于2019年共同平等创立。多位团队成员曾于麦格理量化对冲基金部门工作。目前, ARP在香港及悉尼共拥有27名成员,负责管理亚洲、欧洲及日本逾7亿美元的资金。ActusRayPartners採用的「自主概率投資」方式綜合了:1)量化基礎;以及2)自主調整去應對量化投資的盲點。量化基礎使用了基本面、分析員預測、技術及另類數據,並採用高級統計、自然語言處理及人工智能模型。投資經理的自主調整工作專注於應對純粹量化投資的挑戰,而非單純基本面、宏觀或資金流動分析。关于新鸿基有限公司 及 Sun Hung Kai Capital Partners新鸿基有限公司 (香港股份代号:86) (「新鸿基公司」/「本公司」,连同其附属公司「本集团」) 是一家领先的香港金融机构,在另类投资和财富管理领域备受肯定。新鸿基公司成立于1969年,其多元化的投资组合,涵盖公开市场、信贷和另类投资策略(其中包括房地产和私募股权),缔造长期经风险调整回报。凭借其扎根亚洲的传承,新鸿基公司支持和培育该地区优秀且具专业能力的新晋资产管理公司,赋能他们实现卓越表现。集团亦利用其长久以来建立的投资业务专长和丰富资源,透过其家族办公室解决方案,为理念一致的合作伙伴和超高净值投资者提供量身定制的投资解决方案。截至2024年6月30日,集团的资产总值约为395亿港元。 有关新鸿基有限公司更多的资讯,请浏览 www.shkco.com 或关注公司领英。Sun Hung Kai Capital Partners成立于2020年,是新鸿基有限公司旗下受香港证监会监管的子公司,持有第一、四及九类牌照。有关详情,请浏览 www.shkcapital.com 或于领英关注Sun Hung Kai Capital Partners。媒体查询,请联络:伟达公共关系顾问林贵珍 +852 9839 6552张梦莹 +852 9794 5751电邮:SHKCo@hkstrategies.com 2024-11-01 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status JCN Newswire

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov 1, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). If the FDA accepts the BLA, the Prescription Drug User Fee Act (PDUFA) action date (target date for completion of examination) will be set.The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils* which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.AD is an ongoing neurotoxic process that begins before and continues after plaque deposition. Data suggest that early and continuing treatment may prolong the benefit of therapy even after plaque is cleared from the brain. This SC autoinjector is expected to be easier for patients and their care partners to use and may reduce the need for hospital or infusion site visits and nursing care compared to IV administration. In addition to potentially maintaining the clinical and biomarker benefits, subcutaneous maintenance dosing may be more convenient for patients and their care partners to continue the treatment.LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE and Great Britain. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU). The US FDA accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly LEQEMBI IV maintenance dosing in June 2024 and set a PDUFA action date for January 25, 2025.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2INDICATIONLEQEMBI® [(lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.For the full press release, visit https://www.eisai.com/news/2024/news202482.html. About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S.,3 Japan,4 China,5 South Korea,6 Hong Kong,7 Israel,8 the United Arab Emirates9 and Great Britain.10 Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU).LEQEMBI’s approvals in these countries was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.11,12 The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P
More
健倍苗苗发布盈喜 预期股东应占综合溢利增加不少于50% ACN Newswire

健倍苗苗发布盈喜 预期股东应占综合溢利增加不少于50%

香港, 2024年11月1日 - (亚太商讯 via SeaPRwire.com) - 健倍苗苗(保健)有限公司(「健倍苗苗」或「公司」;股份代号:2161,连同其附属公司统称「集团」)为香港品牌保健品的领先营销商及分销商,集团今天发布盈喜预告。根据对本集团截至二零二四年九月三十日止六个月的未经审核综合管理账目的初步审阅及董事会目前可得的资料,本集团预期截至二零二四年九月三十日止六个月的股东应占综合溢利(「综合溢利」)将较去年同期增加不少于50%。综合溢利大幅增加主要受惠于集团核心品牌的强劲销售势能,尤其是品牌药分部的何济公和品牌中药分部的保济丸。此外,集团的浓缩中药颗粒业务持续增长也提供进一步支持。这样的亮眼表现反映集团的线下及线上渠道销售及营销策略行之有效,从而把握品牌消费保健产品于香港、澳门及大湾区市场的增长潜力。健倍苗苗拥有多元化产品组合,包括品牌药、品牌中药以及健康保健品。集团持续推进重点策略,其中包括扩展本地和跨境电子商务平台、于香港及大湾区市场中发掘传统中药的机遇、优化产品组合以迎合消费趋势、发挥品牌管理优势,以及加强集团的商业执行力。详情请参阅香港交易所之公告。有关健倍苗苗(保健)有限公司 (股份代号:2161)健倍苗苗是设于香港的品牌医疗保健品推广及分销公司,产品据点遍及大中华、东南亚及其他选定国家。集团拥有丰富的行销专业知识并具备深厚的制药背景,秉承产品功效和品质至上的优良传统,在行业内定位独特,致力于满足消费者的保健需要。作为本地领先的品牌医疗保健品运营商,集团拥有一广泛系列品牌医疗保健品,包括品牌药、品牌中药及健康保健品,其中包括「保济丸」、「何济公止痛退热散」、「德国秀碧除疤膏」、「美德玛宝儿除疤啫喱」、「唐太宗活络油」、「飞鹰活络油」、「十灵丹」、「十灵油」及「镇痛霸祛风活络油」等家喻户晓的传统品牌。而自2021年 5月27日,集团获纳入 MSCI 香港微型股指数成份股。有关集团详情,请浏览:www.jbmhealthcare.com.hk Copyright 2024 亚太商讯 via SeaPRwire.com.
More
Fujitsu and AMD to begin strategic partnership to develop more sustainable computing infrastructure intended to accelerate open-source AI initiatives JCN Newswire

Fujitsu and AMD to begin strategic partnership to develop more sustainable computing infrastructure intended to accelerate open-source AI initiatives

Kawasaki, Japan and Santa Clara, California, Nov 1, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu and AMD (NASDAQ: AMD) today announced that they have signed a memorandum of understanding (MOU) to form a strategic partnership to create computing platforms for AI and high-performance computing (HPC). The partnership, encompassing all aspects from technology development to commercialization, will seek to facilitate the creation of open source and energy efficient platforms comprised of advanced processors with superior power performance and highly flexible AI/HPC software and aims to accelerate open-source AI and/or HPC initiatives.Due to the rapid spread of AI, including generative AI, cloud service providers and end-users are seeking optimized architectures at various price points and power per performance configurations. From end-to-end, AMD supports an open ecosystem, and strongly believes in giving customers choice. Fujitsu has worked to develop FUJITSU-MONAKA (1), a next-generation Arm-based processor that aims to achieve both high performance and low power consumption. With FUJITSU-MONAKA, together with AMD Instinct™ accelerators, customers have an additional choice to achieve large-scale AI workload processing to whilst attempting to reduce the data center total cost of ownership.This collaboration will focus on the three strategic areas of engineering, ecosystems, and business, bringing together Fujitsu’s world-leading supercomputer-based advanced CPU technology with industry-leading AMD GPU technology. Under this collaboration, Fujitsu and AMD will target joint development of innovative computing platforms for AI and HPC by 2027.In addition, based on AMD ROCm™ software, an open-source AI/HPC software stack for GPUs, and Fujitsu’s Arm-based FUJITSU-MONAKA software, Fujitsu and AMD will enhance their collaboration with the open-source community. Both companies seek to advance the development of open-source AI software that is optimized for the AI computing platforms they will provide, and work to expand the ecosystem.Fujitsu and AMD will also collaborate on marketing and co-creation with customers to offer these AI computing platforms globally. In addition, to expand AI use cases and promote the societal implementation of AI, based on the computing infrastructure of FUJITSU-MONAKA and AMD Instinct accelerators, both companies will collaborate to build an open and more sustainable AI/HPC platform ecosystem, including a joint customer center.Through this collaboration, Fujitsu and AMD are bringing their respective world-leading technologies together and will promote open-source AI initiatives by offering more sustainable options in both hardware and software that can be utilized by many companies.Vivek Mahajan, Corporate Vice President, CTO, CPO, Fujitsu Limited, comments:“Through this strategic partnership with AMD, Fujitsu seeks to accelerate open-source AI initiatives with a shared vision of achieving sustainable computing platforms. By combining AMD’s innovative GPU technology with Fujitsu’s low-power/high-performance processor FUJITSU-MONAKA, we seek to create an environment in which more companies will be able to utilize AI while reducing the power consumed by data centers. I believe that this partnership is an important step forward in accelerating Fujitsu’s efforts to achieve a sustainable society.”Phil Guido, EVP, Executive Vice President and Chief Commercial Officer, AMD comments:"By combining our cutting-edge AMD Instinct™ accelerators with Fujitsu’s advanced low-power processors, we are positioned to deliver high-performance and energy-efficient solutions that will benefit our joint AI and HPC customers. Our strategic partnership with Fujitsu not only underscores our commitment to innovation but also highlights our dedication to Japan, where we recognize the importance of local partnerships and expertise. As we continue to expand our relationships in Japan, we are excited about the opportunities to create a more sustainable computing infrastructure that aligns with Japan's technological leadership and commitment to sustainability."(1) FUJITSU-MONAKA :A processor based on the ARM instruction set architecture, employing cutting-edge 2-nanometer technology. It achieves high performance through utilizing Fujitsu’s proprietary many-core architecture for high performance and low power consumption. In addition, by supporting industry standard software through Fujitsu’s collaboration with the open-source community, FUJITSU-MONAKA promotes building an environment in which it is easy to maximize performance. This new technology applied to the FUJITSU-MONAKA is based on results obtained from a project subsidized by the New Energy and Industrial Technology Development Organization (NEDO).About AMDFor more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn and X pages.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesAMD PR agency, Burson JapanE-mail: AMDPR@bcw-global.com Copyright 2024 JCN Newswire via SeaPRwire.com.
More
/重复 – 媒体通告 – 退休人士的新篇章:他在 Grande Vie 彩票中赢得了终身每天 1000 美元!/ Finance

/重复 – 媒体通告 – 退休人士的新篇章:他在 Grande Vie 彩票中赢得了终身每天 1000 美元!/

(SeaPRwire) - 蒙特利尔, 2024年10月30日 – 媒体朋友们受邀与Grande Vie大奖得主见面,他们在10月28日的抽奖中获得了$1,000 每天终生的奖金。 会议将于10月31日星期四上午11点在蒙特利尔谢布鲁克西街500号的Loto-Québec总部举行(艾达·洛芙莱斯室,5楼)。 请发送电子邮件 确认您的出席。 总结 什么: 与Grande Vie大奖得主见面,奖金为每天$1,000终生 何时: 10月31日星期四上午11点 何处: Loto-Québec 艾达 洛芙莱斯室,5楼 500 Rue Sherbrooke Ouest 蒙特利尔 RSVP: 来源和更多信息: Renaud Dugas 发言人及媒体关系总监 Loto-Québec 514-499-5208 SOURCE Loto-Québec本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
癌症试验:重新训练免疫细胞为患者带来个性化医疗突破的新希望 Finance

癌症试验:重新训练免疫细胞为患者带来个性化医疗突破的新希望

(SeaPRwire) - 波士顿, 2024年10月31日 — 在癌症研究领域取得了重大进展,晚期癌症患者从SUPLEXA中受益,SUPLEXA是一种个性化治疗方法,可以训练患者自身的免疫细胞来对抗癌症。 “癌症通常通过抑制免疫系统而占上风。我们的方法改变了这种局面:我们从这种抑制性环境中分离出免疫细胞,在实验室中重新激活其固有的抗癌能力,然后将其返还给患者,”波士顿的Alloplex Biotherapeutics[1]创始人兼首席执行官Frank Borriello博士说。 虽然SUPLEXA背后的科学技术很复杂,但对患者和临床医生的流程却出奇地简单。从患者身上抽取一次50毫升的血液就足以完成一整套SUPLEXA治疗方案。只需使用标准的实验室设备,即可分离患者的白细胞,并在体外(ex vivo)使用Alloplex的专有ENLIST免疫细胞训练技术对其进行“训练”。大约一个月后,增强的血细胞被输注回患者体内,在那里它们不仅会寻找并摧毁此前躲避免疫系统的癌细胞,还会改善患者的整体免疫健康。 该研究的完整结果将在11月的2024年SITC大会上公布。澳大利亚研究表明,没有发生与治疗相关的严重不良事件——考虑到SUPLEXA是由患者自身的免疫细胞制成的,这些细胞仅仅经过训练过程以改善其功能,然后才重新引入患者体内,这并不令人意外。 值得注意的是,除了强大的安全性外,SUPLEXA还改变了各种癌症类型患者的生活。其最显著的结果是在患有特定类型的晚期结直肠癌(CRC)和肾癌(RCC)的患者中观察到的。三名CRC患者获得了显著的临床益处:一名患者获得了完全缓解(CR),另一名患者获得了部分缓解(PR),另一名患者获得了疾病稳定(SD)。“这些患者中许多人持续保持了长达两年的强劲临床反应,”Borriello博士说。 在十名RCC患者中,一名患者获得了部分缓解(PR),六名患者获得了疾病稳定(SD),只有3名患者出现了疾病进展(PD)。其他实体瘤患者,包括黑色素瘤、乳腺癌和肺癌患者,在使用SUPLEXA后也表现出长期疾病稳定(SD)。 虽然本研究没有正式收集生活质量评估数据,但患者报告说他们的健康状况有所改善,疼痛减少,症状控制也得到改善。 对于那些已经用尽所有标准治疗方案的参与患者来说,“SUPLEXA是一种非凡的体验,”首席研究员Rohit Joshi副教授[3]说,他在澳大利亚的三个地点领导了首个人体临床试验[4]。“这也让他们能够继续正常生活,去度假,学习新的爱好,并与家人和朋友共度更多时间,”Rohit Joshi副教授说。 FDA打开前进之门 在FDA鼓励下,Alloplex Biotherapeutics计划于2025年初启动SUPLEXA的II期临床试验。该试验将把SUPLEXA与免疫检查点抑制剂(ICIs)联合用于患有特定类型结直肠癌的患者。目标是在受控的临床环境中测试,SUPLEXA的补充机制是否可以通过放大ICI的有效性来改善患者的预后,ICI是治疗这种类型癌症的标准治疗方法。 注释: Alloplex Biotherapeutics是一家成立于2016年的私营公司,总部位于波士顿,其唯一目标是开发其ENLIST免疫细胞训练平台用于癌症治疗。SUPLEXA细胞是该平台推出的首个候选产品,该平台利用和增强了免疫系统的固有能力, 的完整临床和科学结果将在2024年11月初在美国德克萨斯州休斯顿举行的癌症免疫治疗学会“SITC”会议上公布。摘要#378和#678将在免疫工程研讨会上以及在 Rohit Joshi副教授,医学博士,医学博士,FRACP,FACP,FRCP,是一位出版物丰富、享有盛誉的医学肿瘤学顾问。他是南澳大利亚大学和阿德莱德大学的副教授;以及南澳大利亚癌症研究中心(CRSA)的主任。 该公司首个人体临床试验招募了35名患有各种晚期癌症的患者。这是一项在澳大利亚三个临床地点进行的开放标签、单药、篮子研究,已于2024年6月结束。在澳大利亚进行SUPLEXA试验的三个地点是:(1)南澳大利亚癌症研究中心(CRSA)位于南澳大利亚州阿德莱德;(2)南部肿瘤学研究联合会(SOCRU)位于南澳大利亚州阿德莱德,以及(3)格林斯洛普私人医院/加利波利医疗研究基金会,位于昆士兰州布里斯班。 完整媒体资料包: 广泛的背景资料库、问答、图像(包括头像)和视频可在以下网站获取: 媒体联系电子邮件: 来源:Alloplex Biotherapeutics Inc.本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
BRI 2024年第三季度实现45.36万亿印尼盾利润,业绩基础稳固 Finance

BRI 2024年第三季度实现45.36万亿印尼盾利润,业绩基础稳固

(SeaPRwire) - 雅加达,印度尼西亚, 2024 年 10 月 31 日 — PT. Bank Rakyat Indonesia (Persero) Tbk (IDX: BBRI) 在全球和国内经济挑战中保持了强劲的业绩,2014 年第三季度净利润达到45.36 万亿印尼盾。在10 月 30 日的财务业绩发布会上,BRI 总裁兼董事总经理苏纳索表示:“这一成就得益于 BRI 一直以来专注于加强业绩基础并实施战略举措应对市场动态。” 截至2024 年 9 月,BRI 已发放1,353.36 万亿印尼盾贷款,同比增长 8.21%,其中 81.70%(1,105.70 万亿印尼盾)流向中小企业部门。这一增长也使 BRI 的资产增长了 5.94%,达到1,961.92 万亿印尼盾。“BRI 致力于赋能中小企业,因为它们是国家经济增长的重要支柱,”苏纳索解释说,强调了该银行在构建包容性经济中的作用。 BRI 还改善了资产质量,截至 2024 年第三季度,不良贷款率降至 2.90%,贷款对存款比率降至 11.66%,这得益于严格的风险管理和预警系统。该银行以 215.44% 的不良贷款覆盖率加强了其储备。“BRI 已实施了各种风险缓解措施,从选择性增长到积极的信贷监控和协作解决问题,”他说。在负债方面,BRI 筹集了1,362.42 万亿印尼盾的第三方资金(DPK),同比增长 5.59%。低成本资金(CASA)占主导地位,达到 64.17%,高于去年的 63.64%。 BRI 低成本资金增长的一个关键驱动因素是其通过 BRImo 超级应用程序进行的数字化转型,随时随地提供便捷的银行服务。截至2024 年 9 月,BRImo 已拥有 3714 万用户,交易量同比增长 35.20%,达到4,034 万亿印尼盾。 BRI 还将混合银行业务扩展到服务不足的地区,在 62,227 个村庄拥有超过 102 万个 BRILink 代理商,支持国家金融普惠。从 2024 年 1 月到9 月,这些代理商处理了1,170 万亿印尼盾的交易,来自 8.59 亿次交互。 此外,BRI 在 2024 年第三季度的业绩也得到了强劲的流动性(贷款对存款比率为 89.18%)和资本(资本充足率为 26.76%)的支持。“展望未来,BRI 将谨慎管理流动性,以确保为全球和国内经济挑战做好准备,为进一步增长提供空间,”苏纳索补充道。 “BRI 有信心在 2024 年以积极的姿态收官,专注于加强基础并增强抵御能力,以应对全球和国内挑战,”苏纳索总结道。 有关 BRI 的更多信息,请访问 照片 – 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Standard Uranium Provides Exploration Update Highlighting Successful Project Generation with New Joint Venture Ready Projects Available in 2025 ACN Newswire

Standard Uranium Provides Exploration Update Highlighting Successful Project Generation with New Joint Venture Ready Projects Available in 2025

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 31, 2024) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company")is pleased to provide a summary of work programs on three of it's 100% owned uranium exploration projects currently under option and plans for targeted exploration strategies to continue advancing its uranium portfolio in the Athabasca Basin region, northern Saskatchewan towards discovery.The Company holds more than 233,000 acres of prime exploration real estate across the prolific Athabasca Basin region, which hosts the highest-grade uranium deposits on the planet. The Company boasts an attractive portfolio of uranium exploration projects currently available for option ranging from early-stage to drill-ready projects throughout the Athabasca region, providing turn-key opportunities with permits in hand, First Nations agreements signed, vendors secured, and highly prospective uranium targets. Standard Uranium has continued to deliver on its project generator model in 2024 through expansion of landholdings and advancement of early-stage projects through geophysical surveys to be executed this fall, providing excellent turn-key opportunities for potential joint venture partners. The Company is actively seeking new joint venture partners on these exciting uranium projects.Additionally, the Company successfully completed three joint venture earn-in partnerships on the Sun Dog, Canary, and Atlantic projects this year, totalling over $23.8M in work commitments over the next three years. The Company advanced all three projects by successfully operating and completing exploration drill programs on time and under budget. Standard Uranium brings a skilled team of in-house geoscientists and invaluable relationships with First Nations partners and vendors to the table in designing and executing option agreements.2024 Exploration Summary and ObjectivesProject Generator: Completed four definitive option agreements on four projects, securing exploration expenditures and non-dilutive cash-flow into the Company - Sun Dog, Atlantic, Canary, and Brown Lake projects.Aggressive Exploration: Successfully planned and operated three drill programs on Sun Dog, Atlantic, and Canary returning promising results of uranium mineralization and prospective geology, all of which were partner-funded and successfully operated by the Company.Additional Project Advancement: Initial exploration and geophysical programs on the early-stage Rocas and Corvo projects is planned for the fall, creating more opportunities for additional option partnerships.Expanded Landholdings: The Company added nearly 45,000 acres of prospective land to its portfolio in 2024 through low-cost staking, expanding the Ascent and Corvo projects significantly, and adding four new projects to its exploration pipeline in the Athabasca Basin region."We are pleased to share that we are continuing to advance additional uranium exploration projects through targeted geophysical survey work and new staking, which provide more opportunities for new joint venture partners looking to enter the Athabasca Basin. This part of our business represents an outstanding opportunity for companies that want to explore in the world's best uranium jurisdiction with our team at Standard Uranium," said Jon Bey, CEO & Chair of Standard Uranium. "We have built strong relationships with government and our First Nations partners allowing for expediting permitting, along with the key vendors to ensure exploration projects are completed on time and on budget." Figure 1. Overview of the eastern Athabasca Basin region highlighting Standard Uranium's projects under option and available for JV.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10633/228449_c6974358c4f45b18_002full.jpgEastern Athabasca Basin Exploration Highlights & OpportunitiesAtlantic Project - ATCO Mining Option (CSE: ATCM)Uranium Mineralization Confirmed: Analytical results from the winter 2024 drill program at the Project confirmed highly anomalous uranium in drill holes ATL-24-002, ATL-24-004A, and ATL-24-005A, coinciding with prospective structural zones and favorable alteration including dravite-rich clays.Sandstone & Basement-Hosted Uranium: Multiple zones of elevated uranium linked to the sub-Athabasca unconformity and basement structural zones were intersected, indicating a uranium-fertile system.Uranium Pathfinders: Several key uranium pathfinder elements are present in anomalous quantities in multiple drill holes, providing vectoring information for future programs. Intersections of dravitic-clay associated with structural zones has been confirmed in drill holes ATL-24-002, ATL-24-004A, and ATL-24-005A.Verified Targets: Massive structural disruption confirmed in the sandstone column and multiple wide (>10 metres) brittle-reactivated graphitic shear zones confirm the main interpreted electromagnetic ("EM") corridor on the western claim block which was not reached by previous operators. The inaugural program results have confirmed the Company's exploration thesis on the Project, highlighting a uranium-fertile system with several kilometres of still untested strike length across the Project.Follow Up Targets & Next Steps: Atlantic holds significant upside for discovery along the untested portions of the E-W conductor system. Supplementary geophysical surveys over the central claim blocks are currently being planned and will provide further target areas for phase II and III drilling, along with the additional untested gravity low anomalies on the western block identified in 2022.Canary Project - Mamba Exploration Option (ASX: M24)Uranium Mineralization Confirmed: Analytical results from the spring 2024 drill program at the Project confirmed moderately anomalous uranium in drill holes CAN-24-001 and CAN-24-003 with Uranium:Thorium ("U:Th") ratios ≥3:1, indicating hydrothermal uranium input.Basement-Hosted Uranium: Multiple zones of elevated uranium linked to structural zones and/or proximal to lithological contacts, indicating a uranium-fertile system.Elevated Uranium Pathfinders: Several key uranium pathfinder elements are present in anomalous quantities in multiple drill holes within the crystalline basement, providing vectoring information for future programs; anomalous Boron is particularly common. Spectroscopy confirms presence of fracture-hosted dravitic-clay (13.4%) associated with semi-pelitic gneiss in drill hole CAN-24-001.Follow Up Targets & Next Steps: Canary holds significant upside for discovery along three different and significantly underexplored conductor systems. Supplementary geophysical surveys over all three corridors will provide further target areas for phase II and III drilling.Brown Lake - Mustang Energy Acquisition Agreement (CSE: MEC)Project Monetization: Acquired in 2023 via low-cost staking, Standard Uranium sold 90% of the 312-hectare Brown Lake project to Mustang Energy for 60,000 common shares in Mustang and retains a 10% free carried interest in the project, providing future discovery upside potential.Shallow drill targets: 300 counts per second ("cps") were intersected in seven of eight drill holes - Geochemical assays still pending.Prospectivity Model Confirmed: Elevated radioactivity and increased hydrothermal alteration at Wishbone are largely associated with stacked graphitic structural zones, indicating favorable corridors for fluid movement and uranium deposition across the Project akin to other basement-hosted Athabasca deposits.Discovery of Radioactivity: Occurrences of strong to intense radioactivity in outcropping graphitic basement rocks were identified at surface while prospecting at the Wishbone target area:Approximately five kilometres of strike length along a regional scale anticline, defined by strong VTEM conductors with associated radioactivity along each fold limb.Graphitic pelites have been mapped along both fold limbs, hosting strong radioactivity up to 22,300 cps (RS-125 handheld scintillometer).Mineralized cross-cutting faults have been mapped in the overlying rocks which intersect the uranium-bearing graphitic pelite unit.Historical outcrop sampling at the northwestern graphitic pelite exposure returned assay results of 0.32% U3O8 and 0.30% Cu (SMDI #2095).Unrealized Potential: The targets tested during the summer 2024 program represent only a small fraction of the dozens on the ground and the Company is working with its option partners to prioritize follow ups for additional geophysics and drill programs to further test these promising areas.Davidson River Project - Flagship ProjectIn 2023, the Company expanded its flagship Davidson River project in the southwest corner of the Basin to cover more than 37,700 hectares. Standard Uranium plans to follow up on prospective drilling results from 2022 and test brand new high-priority targets akin to the neighboring JR Zone discovery within the new southeast claim blocks.The summer 2022 program revealed the best intersections of prospective alteration and structure to date along the Bronco and Thunderbird trends, including wide graphitic structural zones on Bronco and oxidized alteration on Thunderbird, in addition to elevated radioactivity and dravite alteration.Planned 2025 drilling will follow up on the most prospective basement structures and alteration zones intersected to date and begin testing new target areas within recently staked claim blocks.Data-driven machine learning techniques will contribute to drill targeting at Davidson River through anomaly detection and mapping of EM data, in addition to anomaly matching based on the footprints of known world-class uranium deposits in the area including the Arrow and Triple-R deposits. The machine learning techniques will also be applied to the Company's internal drilling and geochemical databases.Several kilometres of graphitic conductors remain to be tested at Davidson River, with Davidson River still containing massive blue-sky potential for high-grade discovery akin to the Arrow Deposit on the neighbouring Rook I project owned and operated by NexGen Energy Ltd.Harrison Project - Available for OptionSize & Location: Two mineral claims totalling 1,750 ha, located 22 km SSE of the Shea Creek uranium deposits and approximately 30 km SE of the past producing Cluff Lake uranium mine.Geophysical/Geological Signatures: Electromagnetic ("EM") surveys conducted in 2006-2007 outlined multiple EM zones across the project. Harrison covers approximately 6.8 km of a NW-SE conductor trends coincident with a prominent magnetic low. The trend is crosscut by several interpreted fault zones, including 4.9 km of the major Harrison fault.Prospectivity Model: The project has never been drilled and provides the Company with additional exploration exposure in the southwest Athabasca uranium district. The Company believes the newly acquired Harrison project is prospective for the discovery of high-grade* unconformity-related uranium mineralization.Stock Option and RSU GrantsThe Company also announces that, pursuant to its Omnibus Incentive Plan, it has granted stock options (the "Options") to certain directors, management, and consultants of the Company to purchase an aggregate of 367,500 common shares of the Company at the price of $0.10 per common share until October 31, 2029. Vesting of the stock options shall be as follows: 20% of the Options shall vest immediately, with a further 20% of the Options vesting every three months thereafter.In addition to the Options, the Company has also granted 1,325,000 restricted share units (the "RSUs") to certain directors and senior officers of the Company. The RSUs entitle the holder to receive one common share, the cash equivalent or a combination thereof, on the vesting date of October 31, 2025.*The Company considers uranium mineralization with concentrations greater than 1.0 wt% U3O8 to be "high-grade".** The Company considers radioactivity readings greater than 300 counts per second (cps) to be "anomalous".***Natural gamma radiation in outcrop reported in this news release was measured in counts per second (cps) using a handheld RS-125 super-spectrometer and a downhole Reflex EZ-Gamma probe. Readers are cautioned that scintillometer and gamma probe readings are not uniformly or directly related to uranium grades of the rock sample measured and should be treated only as a preliminary indication of the presence of radioactive minerals.The scientific and technical information contained in this news release has been reviewed, verified, and approved by Sean Hillacre, P.Geo., President and VP Exploration of the Company and a "qualified person" as defined in NI 43-101.Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company's future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects.About Standard Uranium (TSXV: STND)We find the fuel to power a clean energy futureStandard Uranium is a uranium exploration company and emerging project generator poised for discovery in the world's richest uranium district. The Company holds interest in over 233,455 acres (94,476 hectares) in the world-class Athabasca Basin in Saskatchewan, Canada. Since its establishment, Standard Uranium has focused on the identification, acquisition, and exploration of Athabasca-style uranium targets with a view to discovery and future development.Standard Uranium has successfully completed three joint venture earn in partnerships on their Sun Dog, Canary, and Atlantic projects totaling over $23.8M in work commitments over the next three years from 2024-2027.Standard Uranium's Sun Dog project, in the northwest part of the Athabasca Basin, Saskatchewan, is comprised of nine mineral claims over 19,603 hectares. The Sun Dog project is highly prospective for basement and unconformity hosted uranium deposits yet remains largely untested by sufficient drilling despite its location proximal to uranium discoveries in the area.Standard Uranium's Davidson River Project, in the southwest part of the Athabasca Basin, Saskatchewan, comprises ten mineral claims over 30,737 hectares. Davidson River is highly prospective for basement-hosted uranium deposits due to its location along trend from recent high-grade uranium discoveries. However, owing to the large project size with multiple targets, it remains broadly under-tested by drilling. Recent intersections of wide, structurally deformed and strongly altered shear zones provide significant confidence in the exploration model and future success is expected.Standard Uranium's eastern Athabasca projects comprise over 42,384 hectares of prospective land holdings. The eastern basin projects are highly prospective for unconformity related and/or basement hosted uranium deposits based on historical uranium occurrences, recently identified geophysical anomalies, and location along trend from several high-grade uranium discoveries.For further information contact:Jon Bey, Chief Executive Officer, and ChairmanSuite 918, 1030 West Georgia StreetVancouver, British Columbia, V6E 2Y3Tel: 1 (306) 850-6699E-mail: info@standarduranium.caCautionary Statement Regarding Forward-Looking StatementsThis news release contains "forward-looking statements" or "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Forward-looking statements include, but are not limited to, statements regarding: the timing and content of upcoming work programs; geological interpretations; timing of the Company's exploration programs; and estimates of market conditions. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements are highlighted in the "Risks and Uncertainties" in the Company's management discussion and analysis for the fiscal year ended April 30, 2024.Forward-looking statements are based upon a number of estimates and assumptions that, while considered reasonable by the Company at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies that may cause the Company's actual financial results, performance, or achievements to be materially different from those expressed or implied herein. Some of the material factors or assumptions used to develop forward-looking statements include, without limitation: that the transaction with the Optionee will proceed as planned; the future price of uranium; anticipated costs and the Company's ability to raise additional capital if and when necessary; volatility in the market price of the Company's securities; future sales of the Company's securities; the Company's ability to carry on exploration and development activities; the success of exploration, development and operations activities; the timing and results of drilling programs; the discovery of mineral resources on the Company's mineral properties; the costs of operating and exploration expenditures; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); uncertainties related to title to mineral properties; assessments by taxation authorities; fluctuations in general macroeconomic conditions. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Any forward-looking statements and the assumptions made with respect thereto are made as of the date of this news release and, accordingly, are subject to change after such date. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228449 Copyright 2024 ACN Newswire via SeaPRwire.com.
More

非洲农村地区,新的人工智能非营利组织项目旨在帮助教师和农民

(SeaPRwire) - 在过去的一年里,马拉维的农村农民一直在向一个生成式人工智能聊天机器人咨询有关他们的作物和牲畜的问题。这些农民用他们的母语奇切瓦语提问,而这个名为“Ulangizi”的应用程序则使用基于政府农业手册信息的对话式语言进行回答。“过去,我们可能要等上好几天才能让农业推广人员前来解决我们农场遇到的任何问题,”马拉维农民马龙·加莱塔说。“现在,只要轻轻一点按钮,我们就能获得所有需要的信息。” 该应用程序背后的非营利组织“机会国际”希望将类似的基于人工智能的解决方案推广到其他贫困社区。今年 2 月,“机会国际”为全球人道主义工作者举办了一个加速孵化器项目,鼓励他们提出基于人工智能的想法,并在来自微软和亚马逊等机构的导师的帮助下进行开发。10 月 30 日,“机会国际”宣布了该项目的三个获奖者:三个免费的应用程序,旨在帮助非洲农民进行作物和气候策略、教师进行课程计划以及学校领导进行行政管理。每个获奖者将获得大约 15 万美元的资金,用于在其社区试点这些应用程序,目标是在两年内覆盖数百万人口。 “机会国际”首席技术官格雷格·尼尔森希望该项目能展示人工智能的力量,为那些以前难以获得知识和专业知识的人创造公平的竞争环境。“自从移动电话出现以来,这是我们一生中见过的最大的民主化变革,”他说。 今年 2 月初,“机会国际”来自世界各地的员工参加了孵化器项目的头脑风暴会议,产生了超过 200 个想法。许多员工希望利用生成式人工智能的潜力来解决他们长期以来在高贫困地区为客户解决的具体问题。例如,提供针对性建议并根据特定语言和经过验证的文档进行训练的语音聊天机器人,对于识字率有限的社区尤其有用。“我们的客户永远不会使用谷歌,”尼尔森说。“现在,他们可以用自己的语言说话,并被用自己的语言回答。” 随后,排名前 20 的团队在大型科技公司导师的帮助下,并借助麻省理工学院平台的技术支持,将他们的想法转化为应用程序原型。由一个评审小组选出了三个获奖者,这些应用程序目前还没有正式名称。第一个获奖者是一款农业应用程序,希望改进“Ulangizi”。虽然“Ulangizi”提供了通用的知识,但这个应用程序将被设计为获取个性化的数据,并根据农民的耕地面积、作物历史和气候提供具体的农业建议——比如种植什么种子、何时以及使用多少肥料。 该项目的创始人之一、驻乌干达的丽贝卡·纳卡瓦表示,该应用程序实时了解气候模式的能力至关重要。“当我们去农民那里时,我们认为最大的问题是定价,”她说。“但我们非常惊讶,因为他们告诉我们,他们最大的问题是气候:找到应对不同气候变化的方法。我们知道,有了人工智能,这是可以实现的。”她希望在明年夏天,在卢旺达和马拉维的种植季节开始之前,这款应用程序能够投入使用。 第二个应用程序帮助教师开发适合学生个性的课程计划。该应用程序由在加纳农村学校任教的洛迪娜·奥曼亨·吉马领导。她发现,教师面临着资源严重缺乏和如何满足不同年龄和学习方式学生的课堂需求方面的知识不足的问题。她的应用程序允许教师输入关于学生学习方式的信息,然后根据国家学校课程生成课程计划。奥曼亨·吉马希望在下一个学年之前,在加纳和乌干达的教室中推广该应用程序。 第三个应用程序旨在帮助各地区的学校领导者,从教师招聘到市场营销到行为管理等各个方面。前肯尼亚教师安妮·尼吉尼希望该应用程序能够成为“学校领导者的口袋里的伙伴,为他们提供实时的解决方案和想法。”“机会国际”表示,该应用程序已准备好推广到 20,000 所学校,可能覆盖 600 万名学生。 这些应用程序的成功还远未得到保证。农村地区的人们往往缺乏智能手机或移动网络连接。(“机会国际”的一位代表表示,这些应用程序将被设计为离线使用。)对于人工智能的新用户来说,学习曲线非常陡峭,而且模型有时会给出错误的答案,这在教育环境中可能是个问题。尼尔森希望,在特定数据集上训练这些人工智能,并与客户一起训练,能够产生更好、更准确的结果。 尼尔森的目标是,孵化器项目每年推出三款基于人工智能的应用程序。但这取决于慈善家和企业合作伙伴的资金。(“机会国际”拒绝透露迄今为止为该项目筹集了多少资金。) 这三个获奖应用程序的创始人都相信,他们已经找到了一个变革性的现实生活中的人工智能应用场景,而这个行业的实际影响力往往被过分炒作所夸大。“我们不只是因为人工智能很流行,每个人都在做,所以才喜欢用它,”奥曼亨·吉马说。“我们身处一线。我们每天都在与这些客户合作,我们知道他们需要什么。”本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

美国首次在猪体内发现禽流感

(SeaPRwire) - 纽约——美国农业部周三表示,在俄勒冈州的一个农场发现了一只猪感染了禽流感。这是该病毒首次在美国猪身上被发现,引发了人们对禽流感可能对人类构成威胁的担忧。 感染发生在克鲁克县的一个后院农场,该农场位于该州中部,不同动物共用水源并住在一起。上周,该农场的家禽被发现感染了该病毒,本周的检测发现,该农场五只猪中的一只也感染了该病毒。 该农场已被隔离,所有五只猪都被安乐死,以便进行进一步的检测。这并非商业化农场,美国农业官员表示,他们不担心该国猪肉供应的安全性。 但布朗大学流行病研究员詹妮弗·努佐表示,在猪身上发现禽流感引发了人们的担忧,即该病毒可能正在迈向成为对人类更大威胁的踏脚石。 她解释说,猪可能感染多种类型的流感,而这些动物可能在使禽类病毒更适应人类方面发挥作用。努佐指出,2009 年的 H1N1 流感大流行起源于猪。 “如果我们试图领先于这种病毒,防止它对公众构成威胁,那么了解它是否在猪体内至关重要,”努佐说。 美国农业部已对该农场家禽进行了基因检测,尚未发现任何表明该病毒正在增强其向人传播能力的突变。官员表示,这意味着目前对公众的风险仍然很低。 过去,美国以外的猪群中曾报告过一种不同的禽流感病毒株,但它并未引发人类大流行。 “这并非一对一的关系,猪感染了病毒就会引发大流行,”宾夕法尼亚州立大学研究人员特洛伊·萨顿说,他研究动物中的流感病毒。 这种禽流感病毒——被称为 A 型 H5N1——在美国野生鸟类、家禽、牛以及许多其他动物中广泛传播。官员表示,其持续存在增加了人们暴露于该病毒并可能感染该病毒的可能性。 专家表示,鉴于如此多的其他动物感染了该病毒,检测到猪感染并非一定令人惊讶。 萨顿说,俄勒冈州猪感染“值得注意,但它是否改变了对威胁程度的计算?不,没有”。如果该病毒开始在猪群中更广泛地传播,并且随后出现人类感染,“那么我们将更加担忧”。 今年迄今为止,美国已报告近 40 例人类感染病例,主要症状为轻微症状,包括眼红,发生在美国加利福尼亚州、科罗拉多州、华盛顿州、密歇根州、德克萨斯州和密苏里州。除了一个人之外,其他人都与感染动物有过接触。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Mazda Launches Redesigned Corporate Website JCN Newswire

Mazda Launches Redesigned Corporate Website

HIROSHIMA, Japan, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation today launched a redesigned corporate website. Amid growing awareness and interest in sustainability, the company redesigned its website to provide stakeholders visiting the corporate website with more timely and user-friendly access to financial and non-financial data as well as information about initiatives set to enhance both corporate and social value.Within the corporate website, it also set up MAZDA MIRAI BASE, a new owned-media platform filled with videos and photos, to share stories about Mazda’s work to build a better future.Mazda Motor Corporation Website URL:Japanese - www.mazda.com/ja/English - www.mazda.com/en/MAZDA MIRAI BASE URL:Japanese - www.mazda.com/ja/mazda-mirai-base/English - www.mazda.com/en/mazda-mirai-base/Key ImprovementsMazda’s website that presents the company’s worldview more clearly offering enhanced usabilityTo help our stakeholders quickly find information they need and access a broader range of corporate data, Mazda redesigned its website structure and reorganized the information posted. In addition, the content was optimized to convey Mazda’s corporate philosophy, established last year, and value creation approach, arranging these in a restructured corporate website that articulates our worldview seeking to create a vibrant future.New MAZDA MIRAI BASE platformThis new owned-media platform MAZDA MIRAI BASE has been created to share Mazda’s aspirations and initiatives for realizing its corporate philosophy and 2030 Vision. Working from the concept of a “media platform that connects with partners to create an exciting future,” MAZDA MIRAI BASE distributes articles, video and photos to tell stories about ”creating the joy of living” found in manufacturing safe and reliable automobiles, manufacturing sustainably, and creating moving experiences.Mazda will continue to pursue the ‘Joy of Driving’ under its core value “Human Centric,” and aim to deliver the ‘Joy of Living’ by creating moving experiences in customers' daily lives.Reference:Mazda’s Corporate Philosophy- Japanese https://www.mazda.com/ja/about/philosophy/- English https://www.mazda.com/en/about/philosophy/ Copyright 2024 JCN Newswire via SeaPRwire.com.
More
NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents JCN Newswire

NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents

Toyota City, Japan, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Today, Toyota Motor Corporation (hereafter, Toyota) and Nippon Telegraph and Telephone Corporation (hereafter, NTT) have agreed to a joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents.Through their previous collaborations, the two companies have confirmed that they share common values, such as contributing to society through technological and industrial development, a people-centered approach, and global contributions that start in Japan. This time, they will further deepen their collaboration with the aim of achieving a "society with zero traffic accidents" as the first step towards realizing a prosperous mobility society where safety and freedom are in harmony.In order to achieve a society with zero traffic accidents, it is necessary to take an infrastructure-cooperative approach that constantly connects people, mobility and infrastructure, in addition to the advancement of driving support technology based on data-driven technology in cars and the development of future automated driving technology.To achieve both of these things, Toyota is developing Software Defined Vehicles (SDV) with safety and security as the top priority. Alongside the evolution of SDV, it will become more important to build infrastructure such as a high-speed, high-quality communication infrastructure, an AI infrastructure that can collect and intelligently process vast amounts of information, and a computing infrastructure.In this collaboration, NTT, whose strengths lie in the telecommunications, and Toyota will jointly build a "Mobility AI Platform" that combines a seamless communications infrastructure with AI and computing platforms that can intelligently process large amounts of data. By doing so, they aim to connect people, mobility, and infrastructure to realize a safe, secure, and sustainable mobility society with no traffic accidents.Details of the joint initiativeWe will jointly develop and operate the "Mobility AI Platform" and use it in our efforts(1) to achieve a society with zero traffic accidents. The Mobility AI Platform is made up of multiple elements(2).The Mobility AI Platform aims to standardize the mobility field, and we envision that it will be used not only by the two companies, but also by a wide range of industry, government, and academic partners who share the goal of realizing a society with zero traffic accidents.Through this initiative, the two companies expect to invest a total of 500 billion yen by 2030. Starting in 2025, they will begin development of the Mobility AI Platform, and from around 2028 under the three-pronged infrastructure, they will begin social implementation and collaboration with various partners, aiming for widespread adoption from 2030 onwards.(1) Main initiatives aimed at achieving a society with zero traffic accidents- Three-pronged infrastructure collaboration" to prevent collisions at blind intersections, etc.- Development of advanced driving support/future automated driving systems" that are data-driven, with AI learning on its own based on large amounts of driving data(2) Elements that make up the mobility AI platform1. Distributed computing platform (data center)Computing resources (data centers) for analyzing and processing vast amounts of data using AI are installed in distributed locations, utilizing IOWN's optical communication technology. By locating them in areas rich in renewable energy, we can achieve local production for local consumption of electricity, and by achieving high power efficiency in the coordination and processing of distributed computing resources and AI, we can promote the greening of the vast amounts of electricity needed for data analysis and processing.2. Intelligent communication infrastructureA system is being built to coordinate human mobility infrastructure through seamless communication that is suitable for various traffic environments and conditions in urban areas, rural areas, and suburbs. In addition to being highly reliable, it also achieves low-latency communication for large volumes of data.3. AI infrastructureA platform that achieves mobility AI that learns and infers from various data from human mobility infrastructure, based on a "distributed computing infrastructure (data center)" and "intelligent communication infrastructure". Copyright 2024 JCN Newswire via SeaPRwire.com.
More

致丰集团旗下 Deltrix与深圳市海梁科技达成深度战略合作,共拓新能源国际市场

EQS 新闻 via SEAPRWire.com / 2024-10-31 / 18:18 UTC+8 致丰集团旗下 Deltrix与深圳市海梁科技达成深度战略合作 共拓新能源国际市场 [香港 - 2024年10月31日] 致丰工业电子集团有限公司(“致丰集团”或“集团”,股份代号:1710. HK) ,宣布集团旗下的 Deltrix Limited 与深圳市海梁科技有限公司在致丰南沙制造总部正式签署战略伙伴合作协议,本次合作在新能源领域引发了广泛关注,被视为行业内的一次重要战略里程碑。 依据合作协议,双方将在新能源、新能源汽车产品及应用创新领域内就光储直柔超级充电站和综合解决方案进行合作,以共同推动全球新能源产业业务发展,包括但不限于在中国大陆、中国香港、中亚、新加坡、印尼、马来西亚、中东等多个国家和地区的市场展开全面合作,重点聚焦于光储直柔超级充电站产品及综合解决方案的研发、推广与应用。合作初期的重点项目涵盖中亚地区光储直柔充电站建设与运营、香港电动的士之家充电场站建设与运营,以及在国内建设光储充样板间等多个项目。合作模式上,双方依据不同项目的具体需求,合理配置并投入相应的资源和能力,共同打造具有市场影响力的双品牌项目。 在技术研发层面,双方均展现出对前沿技术探索的坚定决心。Deltrix一直致力于新能源技术研发的投入和创新,其研发团队在储能技术、智能充电技术等方面取得了一系列成果。海梁科技则在充储直柔技术方面有着深入研究,其研发的新型储能材料有望进一步提升储能系统的性能。通过双方的技术协同,预计将在未来短期内推出一系列更具竞争力的光储直柔超级充电站产品及综合解决方案,满足市场对新能源基础设施不断升级的要求。 在市场拓展方面,双方凭借各自在不同地区和国家的市场优势以及一带一路政策的有力支持,制定了详细的市场拓展计划。Deltrix在全球多个地区拥有广泛的业务网络,这将为合作项目的市场拓展提供有力支撑。预计在未来三年内,双方合作的光储直柔超级充电站产品及综合解决方案预计将在大亚洲市场实现大规模应用和推广。其中,中国香港地区将会成为双方合作起点的重要市场增长点。此外,中亚地区也是双方未来合作的主战场,Deltrix在中亚已取得较佳的市场开拓成果,双方将借助中亚市场打造示范合作项目,再逐步拓展到全球其它地区。本次合作除了会给双方带来可观的经济效益,还会显著提升双方的品牌知名度和国际影响力。 在产业协同方面,双方的合作将对新能源产业链产生深远影响。Deltrix在产业链上下游拥有丰富的资源和整合能力,在充电桩生产环节具有规模优势,海梁科技在光储直柔系统集成方面具有技术优势. 双方的战略合作可以实现资源的优化配置,降低生产成本,提高生产效率,实现零部件采购的协同,减少中间环节,提高供应链效率。同时,还将促进新能源产业技术标准的统一和规范,推动整个新能源产业朝着更加有序、高效的方向发展,为全球新能源产业的升级和进步贡献重要力量。 Deltrix 与海梁科技的合作是新能源领域的一次重要战略布局,双方将携手共进,抓住新能源产业发展的历史机遇,为全球新能源产业的发展注入新的活力,共同开创一个更加绿色、可持续的未来。 致丰集团主席黄思齐先生寄语:“值此致丰与海梁成功签署合作协议之际,我对双方的合作充满信心。此次合作堪称强强联合,通过新能源业务,我们将实现互惠互利。致丰拥有丰富的资源,在生产和厂房技术方面实力雄厚,并且在海外市场拥有广泛的资源和市场能力。海梁科技在研发技术和系统设计方面表现卓越,特别是在光伏和储能领域有着独特的技术专长。双方的企业文化非常接近,这使得我们成为绝佳的生意伙伴。在新能源和 EMS 方面,我坚信我们拥有巨大的合作空间。我们将携手共进,进一步提升双方的业务层次,共同开创合作共赢的新局面,为行业发展注入新的活力。” 海梁科技董事长胡剑平先生寄语:“在海梁科技与致丰达成合作协议这一令人振奋的时刻,我深感欣喜。致丰作为一家拥有 40 多年工业制造积累的香港上市公司,其深厚的底蕴令人钦佩。在新能源领域的制造更是处于行业领先水平,这为我们的合作奠定了坚实的基础。海梁科技在应用场景方面独具优势,拥有三十多年交通、出行、城市电动化解决方案的经验。我们与致丰在业务上具有很强的互补性,致丰主要提供制造、产品和解决方案,而我们侧重于应用场景。我们非常看重致丰的能力和平台,双方强强联合,借助致丰的平台以及海梁科技股东德国大众集团商用车公司的资源优势,携手出海。我们将整合产业链、优秀的软硬件资源,包括光伏、储能、充电、智能微电网等,真正把中国的新能源经验推向海外,为全球新能源产业的发展贡献我们的力量。” 关于致丰集团 致丰集团为香港先进工业电子零件及产品制造及销售企业,并为香港电子工业供应商中首间企业获工业4.01i级的工业4.0成熟度认证证书,拥有近40年行业经验。集团的主要产品包括:智能充电桩、机电产品及开关电源等,广泛应用于智慧城市系统、医疗保健及再生能源领域。集团并建立良好的声誉,成为众多国际知名品牌信赖的供应商。客户主要来自欧美,部分来自东南亚及中国。其中,集团因应全球发展智慧经济,于2017年起与合作伙伴研发自有电动车充电解决方案Deltrix,并在欧洲市场推出。 如欲查询更多信息,请联络: 投资者关系: Skye Shum - 投资者关系经理 传媒查询: DLK Advisory pr@dlkadvisory.com 文件: 致丰集团旗下 Deltrix与深圳市海梁科技达成深度战略合作 共拓新能源国际市场 2024-10-31 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More
All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024 JCN Newswire

All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024

TOKYO, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that the all-new Triton has been selected as a golden award winner at the VMARK Vietnam Design Awards 2024 in the Best Transportation Design category. This marks the second time that Mitsubishi Motors has won the award, after the Xforce topped the same category in 2023.Established in 2018, the VMARK Vietnam Design Awards is organized by the VDAS Design Association based in Ho Chi Minh City. This year, a jury of 42 internationally renowned design practitioners evaluated design projects from Vietnam and around the world, and each entry was evaluated against the five criteria of innovativeness, eco-friendliness, identity, functionality, and community. The most outstanding designs received the golden award, and this year, 19 projects were selected as gold award winners out of a total of 700 entries.The Triton is Mitsubishi Motors' one-ton pickup truck that traces its roots back to the Forte originally released in 1978. In the 45 years since, this global strategic vehicle from Mitsubishi Motors has sold a cumulative total of approximately 5.7 million units in approximately 150 countries spanning five generations of models. Developed under the product concept of "Power for Adventure," the all-new Triton features a complete overhaul of everything from the interior and exterior design to the chassis, ladder frame and engine, and more. It was first launched in Thailand – where its production site is located – in July 2023 and introduced in Japan in February 2024. The all-new Triton is being rolled out sequentially in 100 countries worldwide.In attending the VMARK Vietnam Design Award 2024 ceremony, Kazuhiro Watanabe, Division General Manager of Sales & Marketing Division, Mitsubishi Motors Vietnam Co., Ltd., commented: “This award is a testament to our 30-year journey of 'Drive ahead together for everyday Adventure' in Vietnam. The all-new Triton embodies this commitment by delivering exceptional quality, innovation, and a driving experience that resonates with the adventurous spirit of the Vietnamese people.”Norihiko Yoshimine, Product Design Director, Mitsubishi Motors, who designed the Triton, cheerfully commented, “The Triton expresses the majestic aura that is distinctively Mitsubishi, possessing both robustness and agility in addition to the toughness and sheer power expected of a pickup truck. Following in the footsteps of the award for the Xforce last year, I am deeply honored that the all-new Triton has earned such high recognition at the VMARK Vietnam Design Awards this year. This award will provide a boost, but we will also continue doing our utmost to promote the Triton’s appeal to even more customers in Vietnam.”VMARK Vietnam Design Awards 2024 Awards Page (only available in English and Vietnamese) https://www.vietnamdesignweek.org/vmark-vietnam-design-week-2024About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website athttps://www.mitsubishi-motors.com/en/ Copyright 2024 JCN Newswire via SeaPRwire.com.
More
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference JCN Newswire

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually.Benefits of Continued Treatment with Lecanemab for People with Early ADIn July 2024 at the Alzheimer's Association International Conference (AAIC) 2024, results from the open-label long-term extension study (OLE) following the core study of the lecanemab Phase 3 Clarity AD study were presented, showing that the mean change from baseline in CDR-SB (global cognitive and functional scale) in the lecanemab treated group relative to the placebo group was -0.45 at 18 months, and at 36 months, this expanded to -0.95 compared to a prespecified natural history** cohort of AD. There was a 30% reduction in the relative risk of progressing to the next disease stage In addition, the tau PET substudy of the lecanemab Phase 3 Clarity AD clinical study showed that with three (3) years of continuous treatment with lecanemab, 59% of patients with no or low tau accumulation in the brain (no tau/low tau) at baseline showed improvement or no decline, and 51% showed improvement from baseline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale.1Clarity AD data presented at CTAD expand on these initial results to include additional measurements resulting from three (3) years of continuous lecanemab treatment in patients with low levels of amyloid accumulation in the brain at baseline (less than 60 Centiloids: low amyloid). These data show that 46% of patients improved or had no decline, and 33% showed improvement from baseline on the CDR-SB. On the ADAS-Cog14 measurement scale, 46% of patients showed improvement or no decline and 43% showed improvement. On the ADCS MCI-ADL, 51% of patients showed improvement or no decline and 48% showed improvement. These results – from no tau/low tau population and low amyloid populations – suggest that earlier initiation of lecanemab treatment may have a positive impact on disease progression of early AD patients and may provide continued benefits to patients with early AD over the long term.2No new safety findings were observed with continued lecanemab treatment over three (3) years. Most amyloid-related imaging abnormalities (ARIA) occurred in the first six (6) months of treatment. After the first six (6) months, ARIA rates were low and similar to ARIA rates on placebo during the placebo- controlled period. With regards to the incidence of ARIA by ApoEε4 status during the continuous treatment, the incidence was higher in ApoE4 homozygotes than in heterozygotes or non-carriers, but rates of new ARIA were decreased after the completion of the 18 months core study as treatment continued, regardless of ApoEε4 status.2Correlation between Protofibrils and Biomarkers for Neurodegenerative Disease in the AD Brain Dual-acting lecanemab is the only early AD treatment available to support neuronal function by clearing the highly toxic protofibrils that continue to cause neuronal injury and death even after plaques have been cleared from the brain. Protofibrils accumulate early in the AD brain and lead to nerve cell function loss, abnormal nerve processes, inflammation, and memory loss. In non-clinical studies, antibodies against protofibrils prevented protofibril-mediated neuronal dysfunction and memory loss.Accurately quantifying the amount of protofibrils in human cerebrospinal fluid (CSF) has been challenging due to their low concentration. As such, a new measurement method was developed by researchers at Eisai to accurately quantify protofibrils in CSF.Utilizing this new method of measurement, the amount of protofibrils in AD CSF correlated more strongly with neurodegenerative disease biomarkers (CSF total tau and neurogranin) than with CSF Aβ42, a biomarker associated with Aβ plaques accumulation, indicating that protofibrils are closely related to synaptic dysfunction. Furthermore, it was observed that protofibrils, unlike plaques, are diffusible. These results suggest that protofibrils induce synaptic dysfunction, playing an important role in neurodegeneration in AD brains.3Lecanemab Treatment for Early AD: Insights from Long-Term U.S. Clinical StudiesDr. Marwan Noel Sabbagh, Moreno Family Chair for Alzheimer's Research and Vice Chairman for Research and Professor, Department of Neurology, Barrow Neurological Institute, presented outcomes of an analysis of the use of lecanemab treatment between January 6, 2023, and July 30, 2024, based on payment claims data from the Komodo Research Database, a medical database in the U.S. In the U.S., lecanemab is used in accordance with the US FDA-approved indication, dosing, and monitoring guidelines. The analysis found that access to lecanemab treatment is expanding and highlighted opportunities to improve access in rural areas and educational outreach for underserved populations.4Dr. David Watson of the Alzheimer's Research and Treatment Center reported on patients who continued to receive lecanemab treatment following the Phase II Study 201 and Phase III Clarity AD study. A total of 136 patients participated in both studies at this center, and 66 patients chose to continue lecanemab therapy, with 13 patients receiving treatment for more than five (5) years and 40 patients receiving treatment for more than three (3) years. More than half of the patients (15/24) who continued treatment with lecanemab for more than three (3) years after the core phase remained in their initial stage of disease. Further, in a survey of 11 patients (or their caregivers) who received lecanemab treatment for more than five (5) years, all patients responded that they were “very satisfied” or “satisfied” with lecanemab treatment. In addition, between 45% and 73% of patients responded that lecanemab treatment made them feel more positive about their daily life, social activities, memory, etc. "frequently" or "very often."5No new long-term safety findings were observed in these multi-year studies.5Progress in the AHEAD 3-45 Study: Improving Screening Eligibility Using Blood Biomarkers and Completing Patient EnrollmentAHEAD 3-45 is a Phase 3 clinical study for individuals with preclinical AD, meaning they are clinically unimpaired but have intermediate or elevated levels of amyloid in their brains. In the study, blood tests, cognitive function tests (PACC-5***), amyloid PET, MRI, and tau PET were used for screening. Based on the amount of Aβ accumulation in the brain as determined by amyloid PET, subjects were assigned to two (2) trials with different dose settings: the A3 trial, for those with borderline Aβ levels in the brain, and the A45 trial, for those with positive Aβ levels in the brain.6Screening with blood biomarker tests was important to improve eligibility for amyloid PET testing in subjects without cognitive impairment. Using plasma Aβ42/40 ratio and p-tau217/tau217 ratio in theinitial screening reduced screening failure on amyloid PET from more than 70% to less than 30%. In particular, plasma p-tau217 was shown to correlate with amyloid PET, supporting its role as a useful blood biomarker to identify elevated amyloid in the brain.6Enrollment for the AHEAD 3-45 study was completed in October 2024.Lifetime Achievement Award Presented to Professor LannfeltProfessor Emeritus Lars Lannfelt of Uppsala University received the CTAD Lifetime Achievement Award in recognition of his pioneering work in scientific discovery and drug development in AD. As part of this award ceremony, he delivered a keynote speech outlining the discovery of the arctic mutation in familial AD, its application to therapeutic strategies targeting protofibrils for AD treatment, and the development of lecanemab.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision- making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline of this progressive, debilitating condition.7 Protofibrils cause injury to neurons in the brain which, in turn, can negatively impact cognitive function through multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.8**ADNI is a clinical research project launched in 2005 to develop methods to predict the onset of AD and to confirm the effectiveness of treatments. The ADNI observational cohort was pre-specified and used during the design of Clarity AD. The cohort represents the exact population of those in Clarity AD study; matched ADNI participants show similar degree of decline to placebo group out to 18 months.***PACC-5 is a composite measure that provides a highly sensitive measure of changes in cognitive function in individuals with preclinical AD.About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates and Great Britain. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU).LEQEMBI’s approvals in these countries were based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.9,10 The mean CDR- SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P
More
为什么霍华德大学对卡玛拉·哈里斯来说是一个特殊的地方 Latest News

为什么霍华德大学对卡玛拉·哈里斯来说是一个特殊的地方

(SeaPRwire) - 今年夏天,在接到民主党总统候选人提名电话后,哈里斯立即行动起来,身穿霍华德大学的连帽衫,开始打电话拉票。 这件连帽衫不仅仅是副总统母校的象征,它也是她竞选历史意义的象征。如果哈里斯赢得选举,她将不仅是美国历史上第一位女总统,而且也是第一位从黑人历史悠久的大学(HBCU)毕业担任此职位的总统。 哈里斯于 1982 年进入霍华德大学,获得了经济学和政治学学士学位。她一直将霍华德大学的时光称为她的“ formative years”,是她第一次发现对政治的热爱。“对我来说,霍华德是我的家,”哈里斯在 2021 年 1 月的一篇 Instagram 帖子中写道,回忆起她第一次竞选学生职位和积极参与学生活动的经历。“霍华德教会我,虽然你经常会发现你是房间里唯一一个看起来像你的人,或者是你唯一一个拥有过你所经历过的人,但你必须记住:你永远不会孤单。” 霍华德大学是美国大约 107 所 HBCU 之一。虽然许多 HBCU 都面临着资金短缺的问题,但哈里斯利用她在白宫的平台支持这些机构。今年早些时候,哈里斯邀请了霍华德大学的男子篮球队前往白宫,她说投资 HBCU 就是“对我们国家未来多年的实力的投资”。 这种支持是双向的:根据 The Collective PAC 的数据,一个名为“Bison for Kamala”的政治行动委员会(PAC),以霍华德大学的吉祥物命名,由该组织组织,该组织致力于增加黑人在政治中的代表性,截至 10 月 20 日,已经为哈里斯的竞选筹集了 250,000 美元。 多年来,哈里斯一直坚定地支持霍华德大学。2017 年,她宣誓就任加州参议员的那一年,她为该大学的毕业典礼发表了演讲。在她的演讲中,她敦促毕业生开辟自己的道路,并提醒他们霍华德大学“鼓励我们——期望我们——运用我们的声音。” 哈里斯还提到了许多霍华德大学的著名校友,这些校友激励了她——在她的 2019 年回忆录《我们拥有的真理》中,她写道,她决定去霍华德大学,因为她希望自己的职业生涯“有一个良好的开端。还有什么地方比瑟古德·马歇尔的母校更好的地方呢?” 并且,在 2019 年,她正式宣布她将在霍华德大学竞选总统。“一切都是从这里开始的,”她说。(后来她在 2020 年民主党初选中退出竞选,然后被选为现任总统乔·拜登的竞选搭档。) 在她寻求成为美国第一位女总统之际,哈里斯的职业生涯已经充满了第一次——她成为加州历史上第一位非裔美国人和第一位女检察长,以及美国历史上第二位非裔美国人和第一位南亚裔参议员。她将这些成就归功于她在霍华德大学的学习经历。她在 2017 年的毕业典礼演讲中说:“霍华德大学教会我,就像它教给你们一样,你们可以做任何事,你们可以做任何事。”本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Beginner’s Guide to Travel Credit Cards ACN Newswire

Beginner’s Guide to Travel Credit Cards

SINGAPORE, Oct 31, 2024 - (ACN Newswire via SeaPRwire.com) - Whether you're a frequent business traveller who's always on the go or a world explorer looking for your next adventure, a travel credit card can be a great way to make the best of your trips. The right travel credit card can enhance your travel experiences by offering opportunities to earn rewards, redeem rewards on travel expenses, access discounts and deals, and get perks and benefits like lounge access and travel insurance. Learn all about travel credit cards, what they can do for you and how to choose the right one in our guide below.What is a travel credit card?You may have heard of credit cards that offer discounts and savings on fuel, groceries or shopping. A travel credit card is a type of credit card that offers perks and rewards that make travel smooth and convenient. While the exact reward programs differ from one card to the next, what most miles credit cards have in common is that they grant users benefits and redemption opportunities specifically linked to travel.A travel credit card is a great way to turn everyday spending into travel rewards. Generally, a miles credit card or travel card will let you earn points, miles, or cashback on purchases, which you can redeem for travel-related expenses like flight tickets, hotel stays, car rentals, and more. Over time, savvy cardmembers may accumulate enough rewards to cover the full cost of a small vacation. Many travel credit cards also include benefits like complimentary lounge access, travel insurance, and exclusive discounts with partner airlines and hotels.Pros and Cons of a Travel Credit CardProsEarning points and miles: Your miles credit card helps you earn rewards on eligible purchases. If you use your credit card regularly for eligible purchases, your points or miles can add up quickly and bring you significant savings on your next trip.Sign-up bonuses: In addition to regular rewards, your card may offer a welcome bonus that lets you earn a significant number of points/miles if you meet certain spending criteria. These bonuses can provide a great boost to your rewards balance right from the start.Access to Airport Lounges: Your travel credit card may also include complimentary access to airport lounges, allowing you to enjoy a more relaxed travel experience with amenities like refreshments and comfortable seating before your flight.ConsHigh annual fees: Travel credit cards with good benefits may carry higher annual fees than regular cards. You'll need to review the costs and benefits associated with your credit card to decide if the travel benefits are worth the annual fee.Complex rewards systems: Rewards programs are only useful if you know how to use them well. It might take some time and effort to fully understand how to maximize your rewards.How to Choose a Travel Credit CardWhen choosing a travel or miles credit card in Singapore, consider your travel habits and preferences. Start by considering how often you travel. A card with a high fee may be worth it for frequent fliers, but if you only take one or two trips a year, seek out a card with a low or no annual fee with points that don't expire. You'll need to consider what benefits matter to you. Do you value lounge access, or is travel insurance more important? Choose a card that offers benefits that match your needs. Lastly, look for a rewards program that fits in with your lifestyle. If you spend a lot on dining and shopping, look for a card that offers higher rewards in those categories. Additionally, carefully review the points/redemption process before you apply for a travel credit card. A complex redemption process can be off-putting especially if there are many limits placed on redemption.Notice:Opinions, analyses, reviews, or recommendations expressed in this article are those of the select editorial staff's alone, and have not been reviewed, approved, or otherwise endorsed by any third party.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD) JCN Newswire

Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD)

TOKYO, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Madrid, Spain, and virtually. Eisai also announced initiation of a Phase II study (Study 202) on E2814 for sporadic early Alzheimer’s Disease (AD).Impact of the anti-MTBR tau antibody E2814 on tau pathology biomarkers in Dominantly Inherited Alzheimer’s Disease (DIAD)E2814 is an investigational anti-MTBR tau antibody designed to target the MTBR of tau. In AD patients, neurofibrillary tangles (NFT) are a pathological hallmark, and they are believed to spread through synaptically connected pathways in the brain, forming the tau propagation hypothesis. It is thought that tau propagation is drivenby the specific tau species containing MTBR, tau seeds that spread tau pathology to different brain regions important for cognition and function.Eisai conducted a Phase I/II clinical study (Study 103, NCT04971733; 7 participants) of the anti-MTBR tau antibody E2814 in patients with Dominantly Inherited Alzheimer’s Disease (DIAD) beginning in June 2021. This study aimed to evaluate the safety and tolerability of E2814 in DIAD patients, with a primary objective of assessing the target engagement of E2814 with MTBR-tau species in their cerebrospinal fluid (CSF). In addition, pharmacodynamicevaluation was performed using multiple biomarkers related to AD tau pathology. In the study, DIAD patients withclinical symptoms were administered E2814 for 12 to 24 months. Data from the Dominantly Inherited Alzheimer Network Observational Study (DIAN-obs), an observational cohort of DIAD, were used as references to evaluate biomarkers changes in E2814 treatment.Compared to the reference data from DIAN-obs, patients who received E2814 showed approximately 75% and 50% reductions of CSF MTBR-tau243 and p-tau217, respectively, reflecting tau pathophysiology. Additionally, braintau accumulation observed by tau PET was stabilized or trended toward decrease in DIAD subjects administered E2814. These results suggest that E2814 inhibited tau propagation and suppressed the accumulation of tau aggregates in brains of people living with DIAD. This will be further investigated in the ongoing Phase II/III Tau NexGen study (NCT05269394) with DIAD patients and the Phase II 202 study (NCT06602258) with sporadic early Alzheimer’s disease (AD) patients.Initiation of Phase II clinical study (Study 202)In September 2024, Eisai initiated a Phase II clinical study (Study 202) for individuals with early AD in the United States. The study is also scheduled to be conducted in Japan in the future. This study is a placebo- controlled,double-blind, parallel-group, dose exploration study, evaluating the safety, tolerability, and biomarker efficacy of E2814 in people living with early AD receiving lecanemab as a backbone anti-Aβ therapy.Eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of novel medicines based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of affected individuals and their families in diseases with high unmet needs, such as dementia including AD.This release discusses investigational uses of agents in development and is not intended to convey conclusionsabout efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.About E2814An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease- modifying agent for tauopathies including sporadic Alzheimer’s disease (AD). Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals. In addition, E2814 has been selected as an anti-tautherapy in a Phase II/III Tau NexGen study for the treatment of DIAD, conducted by DIAN-TU led by Washington University School of Medicine in St. Louis, is underway.Biomarkers related to AD tau pathologyAs fluid biomarkers related to AD tau pathology, tau containing the residue 243 (MTBR-tau243) and tau phosphorylated at theresidue 217 (p-tau217) in CSF have been reported.1 In addition, positron emission tomography (tau PET), which specifically detects tau aggregates, is used as an imaging biomarker. These biomarkers are included in the Revised criteria for diagnosis and staging of Alzheimer's disease published by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in June 2024.2(1) Horie K, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nat Med. 2023. 29. 1954-1963(2) Jack Jr. CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024. 20. 5143-5169For further information: Media Inquiries:Eisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Inc. (U.S.) Libby Holman+1-201-753-1945Libby_Holman@Eisai.comEisai Europe, Ltd. (UK, Europe, Australia, New Zealand and Russia) EMEA Communications Department+44 (0) 786 601 1272EMEA-comms@eisai.net Copyright 2024 JCN Newswire via SeaPRwire.com.
More
旅行信用卡初学者指南 ACN Newswire

旅行信用卡初学者指南

新加坡, 2024年10月31日 - (亚太商讯 via SeaPRwire.com) - 无论您是经常出差的商务旅行者,还是寻找下一个冒险的全球探索者,旅行信用卡都可以让您的旅行更加充实。合适的旅行信用卡不仅可以帮助您赚取奖励,还可以将奖励用于旅行开销,享受折扣和优惠,并获得诸如贵宾室通道和旅行保险等福利。通过我们的指南,了解旅行信用卡的所有信息、它能为您带来什么,以及如何选择合适的旅行信用卡。什么是旅行信用卡?您可能听说过一些信用卡提供燃油、杂货或购物方面的折扣和优惠。旅行信用卡是一种专门提供与旅行相关的优惠和奖励的信用卡,使旅行更顺畅、更便捷。尽管每种卡的奖励计划有所不同,但大多数旅行信用卡的共同点在于,它们为用户提供特定于旅行的福利和兑换机会。旅行信用卡是将日常消费转化为旅行奖励的好方法。一般而言,旅行信用卡或里程卡允许您在消费时赚取积分、里程或返现,并将其用于旅行相关的开销,如机票、酒店住宿、汽车租赁等。通过长期累积,精明的持卡人甚至可以积攒足够的奖励来支付一小次度假旅行的全部费用。许多旅行信用卡还包括免费贵宾室通行、旅行保险和与合作航空公司及酒店的独家折扣等福利。旅行信用卡的优缺点优点赚取积分和里程:使用里程信用卡可以在符合条件的消费中赚取奖励。如果您经常使用信用卡进行符合条件的消费,积分或里程将很快积累,为您的下一次旅行带来显著节省。开卡奖励:除了常规奖励外,您的信用卡还可能提供开卡奖励。如果您满足一定的消费条件,便可获得大量积分或里程。这些奖励可以从一开始就大大增加您的积分余额。机场贵宾室通行:您的旅行信用卡可能还包含免费机场贵宾室通行,让您在飞行前享受更放松的旅行体验,包括饮品、点心和舒适的座椅等设施。缺点高年费:拥有良好福利的旅行信用卡的年费通常高于普通信用卡。您需要权衡信用卡的费用与收益,以决定旅行福利是否值得支付高额年费。复杂的奖励系统:奖励计划只有在您会使用时才有用。可能需要花费一些时间和精力来充分理解如何最大化您的奖励。如何选择旅行信用卡在新加坡选择旅行或里程信用卡时,需考虑您的旅行习惯和偏好。首先,评估您的旅行频率。对于常常出行的旅客来说,高年费的信用卡可能是值得的,但如果您每年仅旅行一到两次,最好选择年费较低或无年费且积分不会过期的卡。还要考虑哪些福利对您更重要。您是否看重贵宾室通行,或认为旅行保险更重要?选择能够满足您需求的信用卡。最后,寻找适合您生活方式的奖励计划。如果您在餐饮和购物上花费较多,寻找一张在这些类别中提供更高奖励的信用卡。此外,在申请旅行信用卡前,仔细查看积分/兑换流程。复杂的兑换流程可能会让人望而却步,特别是当兑换受到多种限制时。本文中所表达的意见、分析、评论或建议仅代表特定编辑团队的个人观点,未经过任何第三方的审查、批准或其他形式的认可。媒体联系:姓名: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.com职位名称: 经理来源: iQuanti, Inc. Copyright 2024 亚太商讯 via SeaPRwire.com.
More